The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington, 1959 NE Pacific Street, H-375Q, Box 357630, Seattle, WA, 98195-7630, USA.
Department of Hematology, St. Jude Children's Research Hospital, Memphis, USA.
Qual Life Res. 2022 Sep;31(9):2729-2738. doi: 10.1007/s11136-022-03167-2. Epub 2022 Jun 17.
There is a paucity of empirically estimated health state utility (HSU) values to estimate health-related quality of life among individuals with sickle cell disease (SCD). This study aims to map the Pediatric Quality of Life Inventory generic core scales (PedsQL GCS) to HSUs for children and adolescents with SCD in the United States, using published algorithms, and to assess the construct validity of these HSUs against SCD-specific PedsQL scores.
We used the published mapping algorithms identified in four published articles, in which the PedsQL GCS was mapped to either the EuroQol-5 Dimension 3-Level, Youth Version or the Child Health Utility 9-Dimension to obtain HSUs. We employed the algorithms to calculate HSUs for a sample of children and adolescents from the Sickle Cell Clinical Research and Intervention Program. To assess the construct validity of the mapped HSUs in SCD patients, we computed Spearman's correlation coefficient comparing the HSUs with the PedsQL SCD total score and separately with each PedsQL SCD dimension-specific score.
The mean mapped HSU across published algorithms was 0.792 (95% CI: 0.782-0.801). It was significantly higher among children aged 5-12 years than children aged 13-17 years. The Spearman's correlation coefficient for HSUs versus PedsQL SCD total scores was 0.64 (95% CI: 0.57-0.71). Correlations ranged from 0.40 (95% CI: 0.32-0.48) to 0.60 (95% CI: 0.54-0.66) for HSUs versus PedsQL SCD dimension-specific scores.
The existing mapping algorithms show acceptable construct validity in children and adolescents with SCD. Additional algorithms are needed for adults and for specific SCD comorbidities.
目前用于评估镰状细胞病(SCD)患者健康相关生命质量的健康状态效用(HSU)值主要来自实证研究。本研究旨在使用已发表的算法,将美国 SCD 儿童和青少年人群的儿科生存质量量表核心通用维度(PedsQL GCS)与 HSU 进行匹配,并评估这些 HSU 与 SCD 特异性 PedsQL 评分的结构效度。
我们使用了在四篇已发表的文章中确定的已发表映射算法,其中 PedsQL GCS 分别被映射到欧洲五维健康量表 3 级简表(EuroQol-5D 3L)或儿童健康效用 9 维度量表(Child Health Utility 9-Dimension,CHU9D),以获得 HSU 值。我们采用这些算法对 Sickle Cell Clinical Research and Intervention Program 中的 SCD 儿童和青少年样本进行了 HSU 计算。为了评估 SCD 患者中映射 HSU 的结构效度,我们计算了 Spearman 相关系数,比较了 HSU 与 PedsQL SCD 总分以及 PedsQL SCD 各维度特异性评分之间的相关性。
使用已发表的所有算法计算得出的平均映射 HSU 值为 0.792(95%置信区间:0.782-0.801)。该值在 5-12 岁儿童中显著高于 13-17 岁儿童。HSU 与 PedsQL SCD 总分之间的 Spearman 相关系数为 0.64(95%置信区间:0.57-0.71)。HSU 与 PedsQL SCD 各维度特异性评分之间的相关性范围为 0.40(95%置信区间:0.32-0.48)至 0.60(95%置信区间:0.54-0.66)。
现有的映射算法在 SCD 儿童和青少年中具有可接受的结构效度。对于成年人和特定的 SCD 合并症,需要进一步开发新的算法。